ReviewJMA journal2026
Sphingolipid Signaling in Vascular Smooth Muscle Cells during Development and Diseases.
Review in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elastin Regulates Vascular Smooth Muscle Cell Behavior During Development and in Diseases.Pediatrics international : official journal of the Japan Pediatric SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sphingolipids are essential components of the cell membrane that can be metabolized into bioactive metabolites such as sphingosine-1-phosphate (S1P), which function as signaling molecules both inside and outside cells. S1P primarily regulates cell survival, proliferation, migration, and adhesion by binding to S1P receptors (S1PRs). Sphingolipid signaling is essential for normal cardiovascular development, with impaired S1P production or defective S1PRs leading to embryonic lethality in mice due to vascular defects. Abnormal activation of sphingolipid signaling in pathologies such as atherosclerosis and pulmonary hypertension leads to excessive proliferation and migration of vascular smooth muscle cells (VSMCs). Pharmacological inhibition of the S1PR pathway is clinically available. By outlining current knowledge on sphingolipid signaling in VSMCs and its role in associated vascular diseases, this review intends to highlight the need to advance research targeting VSMCs as a potential therapeutic option for cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.